Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie (Q44208606)
Jump to navigation
Jump to search
scientific article published on 13 March 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie |
scientific article published on 13 March 2013 |
Statements
1 reference
Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie (English)
1 reference
Günter Emons
1 reference
Andreas Günthert
1 reference
Falk C Thiel
1 reference
Oumar Camara
1 reference
Hans-Georg Strauss
1 reference
Georg-Peter Breitbach
1 reference
Heinz Kölbl
1 reference
Toralf Reimer
1 reference
Dominique Finas
1 reference
Klaus Rensing
1 reference
Arbeitsgemeinschaft Gynäkologische Onkologie (AGO)
1 reference
13 March 2013
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference